Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale

Current Opinion in Genetics and Development

Volumn 30, Issue , 2015, Pages 1-6

  Barber, Louise J ^a   Davies, Matthew N ^a   Gerlinger, Marco ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

CANCER GROWTH; CLONAL EVOLUTION; COLORECTAL CANCER; DISEASE ASSOCIATION; EVOLUTIONARY ADAPTATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; INTRATUMOR MACROHETEROGENEITY; INTRATUMOR MICROHETEROGENEITY; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; MOLECULAR MECHANICS; NON SMALL CELL LUNG CANCER; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; PATHOLOGY; PROCEDURES; SINGLE CELL ANALYSIS;

CLONAL EVOLUTION; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; SEQUENCE ANALYSIS, DNA; SINGLE-CELL ANALYSIS;

EID: 84920264636     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2014.12.001     Document Type: Review

References (41)

1. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
2. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
3. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue?. Cell Cycle 2009, 8:505-506.
4. Gerlinger M., McGranahan N., Dewhurst S.M., Burrell R.A., Tomlinson I., Swanton C. Cancer: evolution within a lifetime. Annu Rev Genet 2014, 48:215-236.
5. Cibulskis K., Lawrence M.S., Carter S.L., Sivachenko A., Jaffe D., Sougnez C., Gabriel S., Meyerson M., Lander E.S., Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013, 31:213-219.
6. Voet T., Kumar P., Van Loo P., Cooke S.L., Marshall J., Lin M.L., Zamani Esteki M., Van der Aa N., Mateiu L., McBride D.J., et al. Single-cell paired-end genome sequencing reveals structural variation per cell cycle. Nucleic Acids Res 2013, 41:6119-6138.
7. Ni X., Zhuo M., Su Z., Duan J., Gao Y., Wang Z., Zong C., Bai H., Chapman A.R., Zhao J., et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013, 110:21083-21088.
8. Wang Y., Waters J., Leung M.L., Unruh A., Roh W., Shi X., Chen K., Scheet P., Vattathil S., Liang H., et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014, 512:155-160.
9. Schmitt M.W., Kennedy S.R., Salk J.J., Fox E.J., Hiatt J.B., Loeb L.A. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 2012, 109:14508-14513.
10. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014, 32:579-586.
11. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., Dunning M.J., Gale D., Forshew T., Mahler-Araujo B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
12. De Mattos-Arruda L., Weigelt B., Cortes J., Won H.H., Ng C.K., Nuciforo P., Bidard F.C., Aura C., Saura C., Peg V., et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014, 25:1729-1735.
13. Heitzer E., Ulz P., Belic J., Gutschi S., Quehenberger F., Fischereder K., Benezeder T., Auer M., Pischler C., Mannweiler S., et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013, 5:p30.
14. Mateo J., Gerlinger M., Rodrigues D., de Bono J.S. The promise of circulating tumor cell analysis in cancer management. Genome Biol 2014, 15:448.
15. Gerlinger M., Horswell S., Larkin J., Rowan A.J., Salm M.P., Varela I., Fisher R., McGranahan N., Matthews N., Santos C.R., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014, 46:225-233.
16. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
17. Gulati S., Martinez P., Joshi T., Birkbak N.J., Santos C.R., Rowan A.J., Pickering L., Gore M., Larkin J., Szallasi Z., et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol 2014, 66:936-948.
18. Bashashati A., Ha G., Tone A., Ding J., Prentice L.M., Roth A., Rosner J., Shumansky K., Kalloger S., Senz J., et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013, 231:21-34.
19. Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavare S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013, 110:4009-4014.
20. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y., Turashvili G., Ding J., Tse K., Haffari G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
21. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., Kempski H., Moorman A.V., Titley I., Swansbury J., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
22. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
23. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011, 29:2972-2977.
24. de Bruin E.C., McGranahan N., Mitter R., Salm M., Wedge D.C., Yates L., Jamal-Hanjani M., Shafi S., Murugaesu N., Rowan A.J., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014, 346:251-256.
25. Zhang J., Fujimoto J., Zhang J., Wedge D.C., Song X., Zhang J., Seth S., Chow C.W., Cao Y., Gumbs C., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346:256-259.
26. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., Cho J., Suh J., Capelletti M., Sivachenko A., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
27. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993.
28. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg Å., Børresen-Dale A.-L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
29. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
30. Brannon A., Vakiani E., Sylvester B.E., Scott S.N., McDermott G., Shah R.H., Kania K., Viale A., Oschwald D.M., Vacic V., et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014, 15:p454.
31. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
32. Douillard J.-Y., Oliner K.S., Siena S., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., et al. Panitumumab-FOLFOX4 Treatment and RASMutations in Colorectal Cancer. N Engl J Med 2013, 369:1023-1034.
33. Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24.
34. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
35. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
36. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
37. Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., Adejola N., Gurel M., Hicks J., Meeker A.K., et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013, 123:4918-4922.
38. Gerlinger M., Catto J.W., Orntoft T.F., Real F.X., Zwarthoff E.C., Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol 2014, (epub ahead of print). 10.1016/j.eururo.2014.04.014.
39. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4:127ps10.
40. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-1143.
41. Laurent-Puig P., Pekin D., Normand C., Kotsopoulos S.K., Nizard P., Perez Toralla K., Rowell R., Olson J., Srinivasan P., Le Corre D., et al. Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Can. Res. 2014, 10.1158/1078-0432.CCR-14-0983.